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Diabetes is a costly disease that takes a heavy toll both on patients and families, as well as on healthcare resources. It is 
estimated to affect around 3.2 million 
people in the UK and to take up a tenth of 
the NHS budget (Hex et al, 2012). Disease of 
the foot is one of the most frequent com-
plications of diabetes: around 15-25% of 
patients will, at some point, develop foot 
ulceration and infection. Patients with 
diabetes may also develop Charcot foot 
(Box 1).
One of the negative outcomes of dia-
betic foot ulcers (DFUs) is amputation – 
the loss of part or all of the foot, or the foot 
plus a portion of the lower limb (Clerici 
and Faglia, 2016). Among patients with 
DFUs, 5-24% will have an amputation 
(Moawad, 2016) and the number of people 
who require an amputation as a result of 
diabetes is growing worldwide. 
Five-year survival rates for amputees is 
generally low (51%) but it is even lower for 
amputees with diabetes (30.9%) and, among 
Key points 
1 Most diabetic foot ulcers (DFUs) 
result from either 
neuropathy or 
ischaemia – or both 
2Infection is secondary to  
the development  
of a DFU 
3Gangrene is a complication of 
DFUs and often 
precipitates the 
need to amputate 
4 Early and continuous 
assessment of 
patients with DFUs 
is imperative 
5 Wound debridement  
is important to 
promote the healing 
of DFUs
the latter, almost 69% die within five years 
of the amputation (Aulivola et al, 2004).
Pathogenesis
The diabetic foot results from an interplay 
between a number of factors: vascular dis-
ease, neuropathy, trauma and infection – 
the two main ones being peripheral neurop-
athy and peripheral vascular disease (PVD). 
In type 1 diabetes, neuropathy pro-
gresses more rapidly, and structural and 
functional changes are more severe, than in 
type 2 diabetes (Sima, 2008). The under-
lying pathophysiology is complex and 
takes the form of a dying back of the nerves, 
the distal portions of neurons being first 
and more severely affected (Azhary et al, 
2010). Neuropathy can affect the spinal 
cord, although nerve degeneration begins 
in the periphery and sensory nerve injury 
generally precedes motor nerve injury. 
Neuropathy leads to an insensitive and 
sometimes deformed foot, often with an 
irregular walking pattern. Limited joint 
mobility can result in abnormal, 
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higher up, above the knee (Chen et al, 2013). 
Patients with PVD also have impaired 
wound healing. 
Infection
Infection is not a cause but rather a conse-
quence of DFUs: after an ulcer has devel-
oped and broken through the protective 
epidermis, the secondary phenomenon of 
infection can occur, manifesting as a red, 
inflamed and purulent wound. The pres-
ence of an infected ulcer has been shown to 
increase the risk of lower-extremity ampu-
tation by 50% compared with patients who 
had an ulcer that was not infected (Van 
Battum et al, 2011).
Most diabetic foot infections are poly-
microbial but the most common patho-
gens are aerobic bacteria – mainly Staphy-
lococcus species. Osteomyelitis may occur 
as a result of DFUs and this increases the 
likelihood of surgical intervention 
(Gemechu et al, 2013). 
Gangrene often results from ischemia 
in combination with neuropathy, giving 
rise to a neuro-ischaemic foot (Boulton, 
2014). Urgent assessment of the peripheral 
circulation is imperative and if peripheral 
circulation is adequate, local surgery to 
remove gangrenous areas can be 
attempted, although sometimes single 
toes can be left to auto-amputate (fall off 
by themselves). Patients with gangrene 
and severe distal arterial disease will 
require major amputations as the healing 
outcome from local amputations will be 
poor (Boulton, 2014).
Assessment and patient education
Diabetic foot disease is more common in 
males and people over 60 years of age 
(Rathur and Boulton, 2007). In 2005, health 
professionals were encouraged to examine 
the feet of all men aged over 60 with 
diabetes to determine their risk of devel-
oping foot disease  (Boulton et al, 2005). 
Today, because early identification allows 
us to treat ulcers before they become severe 
(National Diabetes Foot Care Audit, 2016), 
it is recommended that all patients with 
diabetes are assessed holistically to identify 
any factors that may promote ulcer devel-
opment (Wounds International, 2013).
Patients with diabetes should inspect 
their feet daily and should be examined by 
a health professional at least once every six 
can eventually lead to soft tissue 
damage and predispose the foot to 
ulceration (Greenman et al, 2005). 
The formation of a callus or hammer 
toe may lead to abnormally bony points 
over which diabetic foot ulcers may com-
monly form.
Autonomic neuropathy causes a 
decrease in sweat production, resulting in 
dry skin; this can lead to the formation of 
cracks and fissures that may become 
infected.
All of these neuropathies increase the 
risk of trauma caused by factors such as 
ill-fitting footwear, walking barefoot, 
injury with foreign objects or scalding 
(Patnaik et al, 2015).
Peripheral vascular disease
Diabetes is associated with an increased 
risk of accelerated atherosclerosis (Kanter 
et al, 2008). As described in part 2 of this 
series, diabetic arteriopathy (fatty streak 
and plaque formation in the artery wall 
leading to narrowing and occlusion of the 
lumen) is associated with dysfunction of 
the endothelial lining of capillaries and of 
the smooth muscle cells in blood vessels. 
Inflammation and hypercoagulation of 
blood are also prominent features of the 
negative impact of PVD. Due to the reduced 
blood flow to the cells of the legs, hallmark 
symptoms include claudication – the pain 
and muscle aching that occurs in the legs 
when a patient walks (Knight et al, 2017). 
Diabetes is most strongly associated 
with PVD below the knee, whereas other 
risk factors (such as smoking and hyper-
tension) are associated with problems 
bio-mechanical loading of the foot. None-
theless, the patient obliviously continues 
walking on a desensitised foot, potentially 
aggravating and precipitating injuries, 
which may result in the development of 
chronic ulcers. 
Dry, cracked fissures and repetitive 
high pressure (particularly in overweight 
patients with type 2 diabetes), can cause 
the skin of the abnormally loaded foot to 
thicken and calluses to form. If these are 
left untreated they can become thicker and 
break down, leading to the development of 
an ulcer or subcutaneous haemorrhage. If 
PVD is present, the result may be a painful, 
ischaemic foot ulcer. If neuropathy is also 
present, then pain perception is altered or 
pain is not perceived at all despite the 
severe peripheral ischaemia (Bit.ly/Diabe-
tesUKNeuropathy).
Nerve damage
Diabetic neuropathy can affect sensory, 
motor and autonomic functions. It creeps 
in slowly, usually going unnoticed by the 
patient (Khanolkar et al, 2008).
Sensory neuropathy renders the foot 
‘deaf and blind’ to stimuli (Khanolkar et al, 
2008), such as discomfort, temperature 
changes or pain.  The progressive lack 
of these sensations allows the foot to 
be subjected to repetitive trauma and 
tissue damage. 
Motor neuropathy leads to: 
●	 Muscle atrophy; 
●	 	Foot deformity caused by an imbalance 
between flexor and extensor muscles;
●	 	Altered foot biomechanics and 
redistribution of foot pressures, which 
Nursing Practice
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Box 1. Charcot foot in diabetes 
Charcot foot is a non-infective, inflammatory syndrome 
characterised by varying degrees of bone and joint 
destruction, fragmentation remodelling, dislocation 
(commonly of the tarsometatarsal joints) and foot 
deformity. It has been reported in around 16% of patients 
with diabetes who have a history of neuropathic 
ulceration (Khanolkar et al, 2008). In susceptible patients 
with underlying neuropathy, the hallmark of Charcot foot 
is mid-foot collapse or ‘rocker-bottom foot’. 
Charcot foot is thought to occur through uncontrolled 
inflammation of the foot leading to osteolysis 
(breakdown of bone), followed by progressive fracture 
and dislocation (Rogers et al, 2011). The increase in blood flow means the affected 
foot feels warmer than the other. This may be accompanied by redness and/or 
swelling. Repetitive trauma to the insensitive foot propagates micro-fractures and the 
deformed foot becomes more prone to ulceration (Moradi et al 2014).
Charcot foot can be diagnosed early through patient history, examination and 
X-rays. Non-surgical treatment options include immobilisation, braces or custom 
shoes, and offloading pressure to help stop bone destruction (Banks, 2013).
“Disease of the foot is  
one of the most frequent  
and most disastrous 
complications of diabetes”
sp
l
X-ray showing Charcot 
foot deformity
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non-viable tissue and infective material 
associated with both free-living bacteria 
and bacterial biofilm. There is well- 
documented evidence of its importance in 
preparing diabetic foot wounds to heal 
(Attinger and Wolcott, 2012). 
Methods include: 
●	 Autolytic debridement;
●	 Sharp debridement;
●	 Surgical debridement
●	 Hydrotherapy;
●	 Utrasound and photo (light) therapy. 
Biological debridement (larval therapy) 
is increasingly recognised as a successful 
way to treat diabetic, neuro-ischaemic 
ulcers, especially those with necrotic 
tissue that may be difficult to debride by 
other means (Boulton, 2014).
Larval therapy
Larval therapy is the application of living 
larvae of the greenbottle fly (Lucilia seri-
cata) on the necrotic and/or infected wound 
bed. It has been shown to be a safe and 
effective method of debridement in DFUs 
(Gottrup and Jorgensen, 2011). A larvae 
dressing is left on for approximately three 
to four days, then reviewed and repeated if 
necessary. Larval therapy often produces 
clean, healthy granulating wounds that 
progress to heal very well (Fig 1).
Previously, larval therapy was consid-
ered for use only after the failure of other 
debridement therapies, but recently there 
is increased interest in its use as a first-line 
treatment due to the growing rate of non-
healing wounds of the diabetic foot (Shi 
and Shofler, (2014). 
There is now an abundance of scientific 
evidence showing exactly how larvae work 
Management
Wound debridement
Debridement of necrotic tissue (cellular 
debris and cells that have died as a result of 
enzymatic processes) is a pre-requisite 
before a wound can heal. It is a key medical 
intervention in the management of chronic 
non-healing wounds (Strohal et al, 2013). 
In wound care for DFUs, the emphasis 
should be on radical and repeated debride-
ment (Wounds International, 2013). Reg-
ular debridement removes wound debris, 
months. Table 1 summarises the key facets 
of DFU assessment. 
The role of health professionals is also to 
give patients the knowledge they need to 
manage their condition and understand the 
importance of lifestyle changes (Knight et 
al, 2017). Patients should also be encouraged 
to clean and moisturise their feet daily 
and wear well-fitting footwear. Educating 
patients and families is a key part of the pre-
vention and recognition of foot problems 
(Schaper et al, 2016; Bakker et al, 2012).
Table 1. Key facets of diabetic foot ulcer assessment
Assessment Details
Examination 
of the ulcer
●  Size and depth of wound
●  Colour of wound
●  Wound exudate
Testing for 
loss of 
sensation
●  Pinprick sensation
●  Light touch
●  Vibration
●  Pressure sensation (monofilament and tuning fork)
Testing for 
vascular 
status
●  Palpate pedal pulses
●  Doppler ultrasound, ABPI (although take note that ABPI may 
sometimes be inaccurate for patients with diabetes)
●  Claudication
Risk factors 
for infection
●  Probe to bone
●  Peripheral vascular disease
●  Malodour
●  Distal gangrene
Structural 
assessment
●  High arched foot
●  Clawed toes
●  Visible muscle wasting
●  Gait changes
ABPI = ankle brachial pressure index.
Source: Adapted from Khanolkar et al (2008)
Fig 1. Diabetic foot ulcer before and after larval therapy
1c. Foot after nine weeks
The wound progressed to healing  
within nine weeks of larval therapy.  
The patient was impressed with how 
rapidly the treatment had worked, and 
delighted that amputation could have 
been avoided.
1a. Foot before treatment
After initial assessment of the wound, 
larval therapy was discussed with the 
patient and it was agreed that this was 
the best treatment option. 
1b. Foot after four days
After four days of larval therapy, the larvae 
were removed, revealing a fully debrided 
wound and an exposed tendon. Swelling 
and inflammation also appeared to have 
diminished.
Source: Images kindly supplied by Kerry Hayward-Jones, clinical specialist podiatrist, Trafford General Hospital, UK.
For more articles  
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in the wound bed, with debridement, 
wound disinfection and acceleration of 
wound healing being listed as the main 
larval actions (Nigam, 2016; Pritchard et al, 
2016). There is also mounting clinical evi-
dence showing that larval therapy effec-
tively and swiftly removes devitalised 
tissue (Mudge et al, 2014; Waniczek et al, 
2013; Zarchi and Jemec, 2012). 
In their meta-analysis, Sun et al (2014) 
concluded that, despite some studies 
having methodological flaws, larval 
therapy significantly shortened healing 
time and improved healing rate of chronic 
ulcers. Tian et al (2013) compared larval 
therapy with standard care for DFUs and 
showed significantly better outcomes in 
the larval therapy group in several catego-
ries, including percentage of DFUs to 
achieve full healing, time to healing and 
amputation rate.
Offloading
Pressure modulation, or offloading, is of 
great clinical importance in the manage-
ment of neuropathic diabetic ulcers; 
recent studies have shown that proper off-
loading can promote DFU healing 
(Cavanagh and Bus, 2010). 
Many offloading tools are available 
including crutches, wheelchairs, total cast 
walkers and air casts. The gold standard 
is considered to be the total contact casting 
(TCC), which has minimal padding and is 
carefully moulded to the shape of the 
foot, distributing pressures evenly over 
its entire surface. Using TCC has been 
shown to heal a higher percentage of 
plantar ulcers faster than standard treat-
ments (Mueller et al, 1989). TCC use is 
contraindicated in patients with ischaemia 
due to the risk of inducing further DFUs 
(NICE, 2015). 
Conclusion
DFUs are one the most serious and costly 
complications of diabetes. The combina-
tion of peripheral neuropathy and PVD – 
which so often accompany diabetes – cre-
ates an unfortunate environment for 
ulceration and infection of the foot, which 
may lead to amputation. It is vital that 
nurses and other health professionals 
know about the pathology, risk factors, 
assessment and treatment of the diabetic 
foot. Imparting good foot care education 
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